Oncotarget

Research Papers:

Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival

Li-Ru He _, Ning-Fang Ma, Jie-Wei Chen, Bin-Kui Li, Xin-Yuan Guan, Meng-Zhong Liu and Dan Xie

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:31181-31190. https://doi.org/10.18632/oncotarget.5070

Metrics: PDF 1262 views  |   HTML 1118 views  |   ?  


Abstract

Li-Ru He1,2, Ning-Fang Ma4, Jie-Wei Chen1,3, Bin-Kui Li1, Xin-Yuan Guan1,5, Meng-Zhong Liu1,2, Dan Xie1,3

1The State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

2Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

3Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China

4Department of Histology and Embryology, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China

5Departments of Clinical Oncology, The University of Hong Kong, Hong Kong, China

Correspondence to:

Dan Xie, e-mail: xiedan@sysucc.org.cn

Keywords: non-small-cell lung carcinoma, CHD1L protein, metastasis, prognosis, gene amplification

Received: May 24, 2015     Accepted: August 14, 2015     Published: August 24, 2015

ABSTRACT

CHD1L (chromodomain helicase/ATPase DNA binding protein 1-like gene) has been demonstrated as an oncogene in hepatocellular carcinoma (HCC), however, the role of CHD1L in non-small-cell lung cancer (NSCLC) tumorigenesis hasn't been elucidated. In this study, the expression and amplification status of CHD1L were examined by immunohistochemistry and fluorescence in situ hybridization respectively in 248 surgically resected NSCLCs. The associations between CHD1L expression and clinicopathologic features and the prognostic value of CHD1L were analyzed. Overexpression and amplification of CHD1L was found in 42.1% and 17.7% of NSCLCs, respectively. The frequency of CHD1L overexpression (53.2% vs. 28.1%, P = 0.002) and amplification (25.2% vs. 8.2%, P = 0.020) in adenocarcinoma (ADC), was much higher than that in squamous cell carcinoma (SCC). CHD1L overexpression was associated closely with ascending pN status (P < 0.001), advanced clinical stage (P = 0.001) and tumor distant metastasis (P = 0.001) in ADCs, but not in SCCs. For the whole cohort and ADC patients, univariate survival analysis demonstrated a significant association of CHD1L overexpression with shortened survival; and in multivariate analysis, CHD1L overexpression was evaluated as a independent predictor for overall survival and distant metastasis free survival. These results suggested that overexpression of CHD1L is positively associated with tumor metastasis of lung ADC, and might serve as a novel prognostic biomarker and potential therapeutic target for lung ADC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5070